Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PRECISION BIOSCIENCES INC Director's Dealing 2022

Sep 9, 2022

34491_dirs_2022-09-09_df443e30-211f-4004-a261-d1e5b4114db3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PRECISION BIOSCIENCES INC (DTIL)
CIK: 0001357874
Period of Report: 2022-09-01

Reporting Person: SMITH J. JEFFERSON (Chief Research Officer)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1902474 Direct
Common Stock 237959 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Employee Stock Option (Right to Buy) $1.18 2027-03-23 Common Stock (23422) Direct
Employee Stock Option (Right to Buy) $11.98 2028-10-11 Common Stock (46845) Direct
Employee Stock Option (Right to Buy) $5.83 2030-08-20 Common Stock (35786) Direct
Employee Stock Option (Right to Buy) $11.34 2031-06-06 Common Stock (25118) Direct
Restricted Stock Units $ Common Stock (9744) Direct
Employee Stock Option (Right to Buy) $4.08 2032-03-02 Common Stock (74197) Direct
Restricted Stock Units $ Common Stock (46720) Direct

Footnotes

F1: Stock options are fully vested as of the date of this report.

F2: The option vested as to 25% of the underlying shares on September 28, 2019 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

F3: The option vested as to 25% of the underlying shares on April 1, 2021 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

F4: The option vested as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

F5: The restricted stock units ("RSUs") vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

F6: The Reporting Person was granted RSUs, which each represents a contingent right to receive one share of the Company's Common Stock.

F7: The option vests as to 25% of the underlying shares on March 3, 2023 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

F8: The RSUs vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.